Suchitra Kamle

Sep 23, 2023 | biorxiv.org | Bing Ma |Madison Bailey |Suchitra Kamle |Gail Schor

AbstractNon-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. In NSCLC, 10-20% of Caucasian patients and 30-50% of Asian patients have tumors with activating mutations in the Epidermal Growth Factor Receptor (EGFR). A high percentage of these patients exhibit favorable responses to treatment with tyrosine kinase inhibitors (TKI). Unfortunately, a majority of these patients develop therapeutic resistance with progression free survival lasting 9- 18 months.